Transcripta Bio and Microsoft Research Collaborate
Transcripta Bio has recently embarked on an exciting collaboration with Microsoft Research aimed at revolutionizing the process of discovering disease-gene associations. By harnessing the power of advanced artificial intelligence (AI) combined with extensive transcriptomic data, both organizations seek to enhance the speed and accuracy of identifying novel therapeutic opportunities.
Combining Expertise for Enhanced Research
This partnership beautifully merges Transcripta Bio's innovative Drug-Gene Atlas, which houses more than a billion gene responses alongside full-transcriptome data, with the cutting-edge machine learning capabilities of Microsoft Research. The objective is clear: identify potential disease-gene links more efficiently than conventional research methodologies can achieve.
Focus on Disease-Gene Associations
In their analysis of chemotranscriptomic datasets, the teams will be concentrating on pinpointing candidate disease-gene associations that are validated through experimental evidence demonstrating modulation of gene expression. This effort is anticipated to significantly shorten the timeline from initial discovery to clinical candidate selection, ultimately allowing for the expedited delivery of new therapies to those in need.
Insights from Microsoft Research Leadership
Scott Saponas, who is the Senior Director and Deputy Lab Director at Microsoft Research Health Futures, expressed enthusiasm regarding the collaboration. He stated, “We are excited to collaborate with Transcripta Bio to leverage our expertise in rare disease genomics and AI, aiming to develop innovative methods for drug discovery that can significantly impact the treatment of rare diseases.”
A Transformative Approach to Drug Discovery
Dr. Chris Moxham, Co-founder and CEO of Transcripta Bio, shared his insights on the collaboration. He said, “This collaboration with Microsoft Research enables us to scale our transcriptomics-driven approach, leveraging Microsoft’s computational resources and AI expertise. Together, we are setting a new standard for the speed, certainty, and efficiency of drug discovery.”
About Transcripta Bio
Transcripta Bio stands as a pioneering AI drug discovery company that focuses on transcriptomics-driven insights for the identification and development of novel therapeutics spanning various disease areas. Utilizing its proprietary AI platform, Transcripta Bio accelerates the process of discovering and validating promising drug candidates, employing both repurposed and novel molecules to create targeted therapeutic solutions.
Contact Information for Media Inquiries
For more information, here’s how you can reach out to Transcripta Bio. Their official website, www.transcriptabio.com, serves as a hub for their latest updates. Additionally, for media inquiries, Transcripta Bio maintains robust communication channels to engage with interested parties.
Frequently Asked Questions
What is the focus of the collaboration between Transcripta Bio and Microsoft Research?
The collaboration aims to enhance the discovery of disease-gene associations using AI and transcriptomic data.
What resources does Transcripta Bio utilize in its drug discovery process?
Transcripta Bio uses its Drug-Gene Atlas, which includes extensive gene response data and full-transcriptome information.
How will this collaboration impact drug discovery timelines?
By integrating AI, the collaboration seeks to shorten the time from discovery to clinical candidate selection, leading to more efficient therapy delivery.
Who are the key leaders involved in this collaboration?
Key figures include Scott Saponas from Microsoft Research and Dr. Chris Moxham from Transcripta Bio.
What is the ultimate goal of this research collaboration?
The ultimate goal is to identify new therapeutic opportunities more quickly and reliably than traditional drug discovery processes.
